Literature DB >> 7889939

Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A.

J R Doedens1, K Kirkegaard.   

Abstract

Poliovirus RNA replication occurs on the surface of membranous vesicles that proliferate throughout the cytoplasm of the infected cell. Since at least some of these vesicles are thought to originate within the secretory pathway of the host cell, we examined the effect of poliovirus infection on protein transport through the secretory pathway. We found that transport of both plasma membrane and secretory proteins was inhibited by poliovirus infection early in the infectious cycle. Transport inhibition did not require viral RNA replication or the inhibition of host cell translation by poliovirus. The viral proteins 2B and 3A were each sufficient to inhibit transport in the absence of viral infection. The intracellular localization of a secreted protein in the presence of 3A with the endoplasmic reticulum suggested that 3A directly blocks transport from the endoplasmic reticulum to the Golgi apparatus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7889939      PMCID: PMC398162          DOI: 10.1002/j.1460-2075.1995.tb07071.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  60 in total

1.  RNA synthesis in poliovirus-infected cells.

Authors:  E F ZIMMERMAN; M HEETER; J E DARNELL
Journal:  Virology       Date:  1963-03       Impact factor: 3.616

2.  Inhibition of endocytic vesicle fusion in vitro by the cell-cycle control protein kinase cdc2.

Authors:  T Tuomikoski; M A Felix; M Dorée; J Gruenberg
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  Cation content in poliovirus-infected HeLa cells.

Authors:  A López-Rivas; J L Castrillo; L Carrasco
Journal:  J Gen Virol       Date:  1987-02       Impact factor: 3.891

6.  Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex.

Authors:  D Etchison; S C Milburn; I Edery; N Sonenberg; J W Hershey
Journal:  J Biol Chem       Date:  1982-12-25       Impact factor: 5.157

7.  Properties of purified recombinant poliovirus protein 3aB as substrate for viral proteinases and as co-factor for RNA polymerase 3Dpol.

Authors:  J Lama; A V Paul; K S Harris; E Wimmer
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

8.  Intracellular distribution of poliovirus proteins and the induction of virus-specific cytoplasmic structures.

Authors:  K Bienz; D Egger; Y Rasser; W Bossart
Journal:  Virology       Date:  1983-11       Impact factor: 3.616

9.  Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF.

Authors:  J B Helms; J E Rothman
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

Review 10.  Gene regulation: translational initiation by internal ribosome binding.

Authors:  S K Oh; P Sarnow
Journal:  Curr Opin Genet Dev       Date:  1993-04       Impact factor: 5.578

View more
  169 in total

1.  Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells.

Authors:  J M Mackenzie; M K Jones; E G Westaway
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  A cysteine-rich motif in poliovirus protein 2C(ATPase) is involved in RNA replication and binds zinc in vitro.

Authors:  T Pfister; K W Jones; E Wimmer
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Infection of polarized cultures of human intestinal epithelial cells with hepatitis A virus: vectorial release of progeny virions through apical cellular membranes.

Authors:  C A Blank; D A Anderson; M Beard; S M Lemon
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Effects of poliovirus infection on nucleo-cytoplasmic trafficking and nuclear pore complex composition.

Authors:  K E Gustin; P Sarnow
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

5.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

6.  Expression of a membrane-anchored glycoprotein, the influenza virus hemagglutinin, by dicistronic replicons derived from the poliovirus genome.

Authors:  Marco Vignuzzi; Sylvie Gerbaud; Sylvie van der Werf; Nicolas Escriou
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Poliovirus protein 2BC increases cytosolic free calcium concentrations.

Authors:  R Aldabe; A Irurzun; L Carrasco
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  Inhibition of nuclear import and alteration of nuclear pore complex composition by rhinovirus.

Authors:  Kurt E Gustin; Peter Sarnow
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.